3.50
6.38%
+0.21
After Hours:
3.50
Galectin Therapeutics Inc stock is currently priced at $3.50, with a 24-hour trading volume of 211.98K.
It has seen a +6.38% increased in the last 24 hours and a +50.21% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.36 pivot point. If it approaches the $3.60 resistance level, significant changes may occur.
Previous Close:
$3.29
Open:
$3.23
24h Volume:
211.98K
Market Cap:
$205.83M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-5.303
EPS:
-0.66
Net Cash Flow:
$-32.97M
1W Performance:
+3.55%
1M Performance:
+50.21%
6M Performance:
+69.90%
1Y Performance:
+100.00%
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
Feb-13-19 | Initiated | B. Riley FBR | Buy |
Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
Oct-19-17 | Initiated | ROTH Capital | Buy |
Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
Mar-28-16 | Resumed | H.C. Wainwright | Buy |
Sep-21-15 | Initiated | H.C. Wainwright | Buy |
Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
Jul-30-14 | Reiterated | MLV & Co | Buy |
Jul-29-14 | Reiterated | MLV & Co | Buy |
Apr-02-14 | Reiterated | MLV & Co | Buy |
Feb-10-14 | Reiterated | Aegis Capital | Buy |
Jan-09-14 | Reiterated | Aegis Capital | Buy |
Dec-03-13 | Initiated | MLV & Co | Buy |
Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
GlobeNewswire Inc.
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
GlobeNewswire Inc.
Galectin Therapeutics Inc Stock (GALT) Financials Data
Galectin Therapeutics Inc (GALT) Net Income 2024
GALT net income (TTM) was -$41.07 million for the quarter ending December 31, 2023, a -5.91% decrease year-over-year.
Galectin Therapeutics Inc (GALT) Cash Flow 2024
GALT recorded a free cash flow (TTM) of -$32.97 million for the quarter ending December 31, 2023, a -6.15% decrease year-over-year.
Galectin Therapeutics Inc (GALT) Earnings per Share 2024
GALT earnings per share (TTM) was -$0.74 for the quarter ending December 31, 2023, a -13.85% decline year-over-year.
Galectin Therapeutics Inc Stock (GALT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ELDRED KARY | Director |
Jan 16 '24 |
Buy |
1.79 |
500 |
893 |
49,313 |
Uihlein Richard E | Director |
Sep 26 '23 |
Option Exercise |
4.49 |
2,236,204 |
10,033,020 |
10,235,495 |
ELDRED KARY | Director |
Jul 19 '23 |
Buy |
1.79 |
1,598 |
2,854 |
48,813 |
About Galectin Therapeutics Inc
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Cap:
|
Volume (24h):